Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/ektNCduTtWCiaacRCidncVCicNSeGY
| Today's Top Story |  |  | | - FDA accelerates review of ViiV's HIV/AIDS drug dolutegravir
ViiV Healthcare, a joint venture of GlaxoSmithKline, Pfizer and Shionogi, obtained priority-review status from the FDA for its investigational daily AIDS/HIV treatment dolutegravir. The drug is an integrase inhibitor that keeps the virus out of cells. The FDA is set to decide on the drug's approval by Aug. 17. Yahoo/Reuters (2/16)       | Health Care & Policy | | | | - Applied Spectral's automated gene scanner wins FDA approval
Applied Spectral Imaging obtained FDA approval to market its GenASIs Scan & Analysis microscopy platform to aid ALK gene analysis for selection of lung cancer treatment. The scanner can be used in genetic analysis of samples with the Abbott Vysis ALK Break Apart FISH Probe test. Abbott's assay is used to determine the presence of ALK-positive nonsmall-cell lung cancer, which may respond to Pfizer's Xalkori. GenomeWeb Daily News (free registration) (2/15) - Astellas-Aveo's tivozanib extends survival in kidney cancer trial
Patients with kidney cancer who took Astellas and Aveo Pharmaceuticals' tivozanib survived without their disease worsening longer than patients who took Bayer and Onyx Pharmaceuticals' Nexavar, or sorafenib, while overall surival was comparable, a clinical study found. The FDA is expected to decide on tivozanib's approval by July 28. PharmaTimes (U.K.) (2/14) - Study to explore stem cell therapy for diabetic retinopathy
A European Union-supported study will explore the use of adult bone marrow stem cells in treating diabetic retinopathy. Researchers are set to grow the cells in the laboratory and plan to transplant them in patients in an attempt to repair damaged blood vessels and retinas and to restore vision. Human trials are slated to be conducted in Denmark after preclinical tests at several sites in Europe. Diabetes.co.uk (U.K.) (2/14) | Company & Financial News | | | | | Food & Agriculture | | | | | Hot Topics | | | | Top five news stories selected by BIO SmartBrief readers in the past week. - Results based on number of times each story was clicked by readers.
| Industrial & Environmental | | | | - Calif. agency gives $17.2M to transportation projects
The California Energy Commission awarded $17.2 million to companies developing cleaner transportation technologies, including biofuels, under its Alternative and Renewable Fuel and Vehicle Technology Program. The program is expected to give about $90 million this fiscal year. BiofuelsDigest.com (2/15) | News from BIO | | | | - Are you taking full advantage of your membership?
BIO's cost-savings program, BIO Business Solutions, is helping 2,700 companies nationwide save on the cost of essential products and services. Members of BIO and 43 state and regional biotech associations are eligible to receive preferential pricing and other benefits at no additional cost beyond their membership dues. VWR International, FedEx, Office Depot and Business Wire are just a few of the industry leading providers that offer special pricing through this members-only program. Learn more or enroll here.
| SmartQuote | | | |  | You will become as small as your controlling desire; as great as your dominant aspiration."
--James Allen,
British author  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Friday, February 15, 2013
- Thursday, February 14, 2013
- Wednesday, February 13, 2013
- Tuesday, February 12, 2013
- Monday, February 11, 2013
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2013 SmartBrief, Inc.® Legal Information |
|
The debate over Washington state's Initiative 522, which would require special labeling for biotech foods, should focus on science, and the evidence doesn't show any risk. 
No comments:
Post a Comment